Drugs / BH011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06732531 | Aug 2022 → Dec 2025 overdue | urinary bladder carcinoma | Zhuhai Beihai Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BH011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06732531 ↗ |
| Route | Other | “BH011 is administered intravesically through a urinary catheter” NCT06732531 ↗ |